Capricor Therapeutics (CAPR): A Cautionary Tale for Biotech Investors Following 67% Drop
Capricor Therapeutics plummets 67% amid FDA concerns, highlighting the high-stakes nature of biotech investments.
Capricor Therapeutics Faces Critical FDA Review: What’s Next for CAPR Investors?
Capricor Therapeutics navigates a critical FDA review, impacting stock dynamics and future growth potential.
OTLK Stock Soars After FDA Approval: What Investors Need to Know
Outlook Therapeutics' FDA approval for its wet AMD drug could signal a significant opportunity for investors in OTLK stock.
Pfizer's Talzenna-Xtandi Filing: A Potential Game Changer in Prostate Cancer Treatment
Pfizer's Talzenna and Xtandi filing could reshape prostate cancer treatment, signaling a strategic expansion in oncology.
BridgeBio Pharma's NDA for Encaleret: A Significant Milestone for Investors
BridgeBio Pharma's NDA acceptance for encaleret marks a pivotal moment for investors, highlighting potential commercialization timelines.
Hims & Hers Stock Surges After FDA Advisory Panel Backs Peptide Compounding
Hims & Hers stock saw a 13% increase following a favorable FDA panel vote on peptide compounding, raising investor optimism.
Outlook Therapeutics: Anticipating a Critical FDA Decision on Lytenava
Investors are closely watching Outlook Therapeutics as the FDA decision on Lytenava for wet AMD approaches, following two previous rejection…
Pfizer's Talzenna-Xtandi Combo: A Game Changer for Prostate Cancer Treatment?
Pfizer's recent FDA approval for Talzenna and Xtandi's combination therapy could reshape prostate cancer treatment and influence its dividen…
Hims & Hers Surges 13%: Analyzing the FDA Panel's Impact on HIMS Stock
HIMS stock jumped 13% after an FDA advisory panel's backing, reflecting bullish retail investor sentiment.
BridgeBio Pharma's NDA Acceptance: A New Investment Frontier for BBIO
BridgeBio Pharma's FDA NDA acceptance for encaleret marks a pivotal moment in biotech, potentially reshaping investor outlook.
Scholar Rock Awaits FDA Decision on Apitegromab: A Key Catalyst for Investors
Scholar Rock's upcoming FDA decision on apitegromab could significantly impact its stock performance, with a PDUFA date set for September 30…
Bristol Myers Squibb Leverages Nvidia AI Chips for Next-Gen Drug Discovery
Bristol Myers Squibb invests in Nvidia's AI technology, signaling a transformative phase in pharmaceutical R&D.